消癌平注射液联合化疗对中晚期肺癌患者CD4~+CD25~+FOXP3~+调节型T细胞的影响

目的探讨消癌平注射液联合化疗对中晚期肺癌患者CD4+CD25+FOXP3+调节型T细胞的影响。方法 71例Ⅲ～Ⅳ期非小细胞肺癌患者随机分为治疗组与对照组,治疗组36例采用化疗联合消癌平注射液;对照组35例单独采用化疗,两组化疗均采用GP方案。完成2周期后,通过流式细胞仪测定两组患者治疗前后外周血中CD4+CD25+FOXP3+调节型T细胞比例。结果治疗后治疗组患者CD4+FOXP3+T细胞占CD4+T细胞及CD4+CD25+T细胞的比例分别为(6.2±2.4)%和(27.6±6.0)%,而对照组分别为(8.2±0.5)%和(32.1±7.6)%,两组比较差异有统计学意义(P<0.05)。CD4+T细胞占总淋巴细胞的比例,治疗组较对照组明显提高(P<0.05)。结论消癌平注射液是一种较为理想的免疫增强剂,联合化疗可明显改善非小细胞肺癌患者的细胞免疫功能。

Influence of Xiaoaiping injection combined with chemotherapy on CD4+CD25+FOXP3+ regulatory T lymphocytes

Objective To explore the influence of Xiaoaiping injection combined with chemotherapy on CD4+CD25+FOXP3+ regulatory T lymphocytes in advanced lung cancer patients.Methods 71 cases withⅢ-Ⅳ stage non-small cell lung cancer were divided into two groups.36 patients of test group were treated with combination of Xiaoaiping injection and chemotherapy.And 35 patients of control group only received chemotherapy.The chemotherapy was GP regimen.The percentage of CD4+CD25+FOXP3+ regulatory T lymphocytes from peripheral blood were evaluated after two circles by Flow cytometer.Results In the test group,the percentage of CD4+FOXP3+ T lymphocytes in CD4+ T lymphocytes and CD4+CD25+ T lymphocytes are(6.2±2.4)% and(27.6±6.0)%,compared with the control(8.2±0.5)% and(32.1±7.6)%,there were significant difference(P<0.05).The percentage of CD4+ T lymphocytes in test group patients was higher than the control group(P <0.05).Conclusion Xiaoaiping injection is an ideal immunopotentiator.It can significantly improve the cellular immunity of non-small cell lung cancer patients.